Loading...
Under maintenance — back shortly
AMPK→remyelination and neuroinflammation suppression
Metformin activates AMPK, which suppresses neuroinflammation and promotes oligodendrocyte progenitor cell differentiation and remyelination — both central to multiple sclerosis pathology. Evidence includes animal models of experimental autoimmune encephalomyelitis and early clinical data, with 8/8 supportive co-mentions and papers up to 2025.
“Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.”
— Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis. (2023)DOI“Metformin rejuvenates adult rat oligodendrocyte progenitor cells (OPCs) allowing more efficient differentiation into oligodendrocytes and improved remyelination, and therefore is of interest as a therapeutic in demyelinating diseases such as multiple sclerosis (MS).”
— Metformin alters mitochondria-related metabolism and enhances human oligodendrocyte function. (2025)DOI“Introduction of metformin into the program of complex therapy of patients with MS, provides more evident correction of the parameters of carbohydrate metabolism, reduction of endothelin-1 and stiffness index of the aortic wall, enhancement of parasympathetic regulation, than modification of the life”
— Possibilities of use of metformin for correction of endothelial dysfunction and adaptation reserves of an organism in patients with metabolic syndrome (2020)DOI“Our findings suggest metformin for combination therapy for patients suffering from the myelin degenerative diseases, especially multiple sclerosis; however, additional mechanistic studies are required.”
— Metformin Protects Myelin from Degeneration in A Mouse Model of Iysophosphatidylcholine-Induced Demyelination in The Optic Chiasm. (2021)DOI